For the first time, a consistent and predictable effect resulted from inhaling meager amounts of medical cannabis, using a metered medical Inhaler and a designated Cartridge containing 60 metered doses of the highest quality cannabis inflorescence grown under strictly controlled conditions.
The SyqeAir Inhaler and Cartridge bring the principles of modern medicine to the cannabis field: Low and metered dose + reproducible composition of ingredients = consistent effect with every inhalation
How does the SyqeAir Cartridge work?
Exclusive: SyqeAir Cartridge receives EU-GMP standard for production of a cannabis product for inhalation
Syqe® is the first Israeli company to receive the European Union Good Manufacturing Practice standard (EU-GMP) for the production of a cannabis product designed for inhalation. The cartridges are manufactured at the Medimor factory, and in January 2024, the production line received certification according to the EU-GMP standard—a strict standard required of all pharmaceutical manufacturers, including medical cannabis, intended for export to the European Union and other countries operating according to this standard. This is world-class news for Syqe® and the Israeli cannabis industry.
The SyqeAir Inhaler and Cartridge make the treatment with medical cannabis simple, convenient, and consistent
- Each Cartridge allows for 60 inhalations and is ready for immediate use – even for breakthrough pain
- Each VaporChip provides a metered dose of THC. Each patient has a personal dose adjusted to them by a nurse out of 4 options: 250, 500, 750, or 1,000 mcg of THC in the aerosol. Selecting the dose is done with the push of a button (found on the front of the Inhaler)
- With each inhalation, the cannabis used is delivered from a new VaporChip (this is in contrast to smoking or using a vaporizer, where you inhale a repeatedly heated/burned cannabis)
- The Cartridge is tamperproof and does not allow for the consumption of the cannabis by any other means except the Inhaler
- The Cartridge saves patients the need to touch and handle the inflorescence directly and does not require special preparations (granulating, rolling, cleaning, etc.)
- Upon the Cartridge, there is a window indicating the number of remaining inhalations
The medical cannabis in the Cartridge: Bedrocan® product –
Standardized cannabis, reproducible from batch to batch
Syqe® company is the only one in Israel that imports the Bedrocan® product.
- Medical cannabis of Bedrocan® Sativa T20C4 product – free from metals, pests, and pesticides
- The cannabis is grown in sterile rooms under strict and controlled conditions, with stringent EU GMP supervision and with no human contact
- Reproducible composition of the THC/CBD ingredients – can be repeated over and over again from batch to batch: that is, SyqeAir patients receive the same composition with each inhalation
- The Bedrocan® product that is inside SyqeAir Cartridges has participated in the largest number of clinical studies worldwide on pain, breathing, safety, and more
To learn more about the Bedrocan® product that is in the SyqeAir Cartridge>> Bedrocan page
The SyqeAir Cartridge ensures a metered and consistent dose with a predictable effect
When patients consume a consistent and low dose (in micrograms) of THC from cannabis inflorescence whose composition of ingredients is reproducible (can be repeated over and over again from batch to batch), they are expected to get a consistent effect after each inhalation. An effect that provides a reduction in pain intensity and improvement in sleep quality, with minimum side effects (if at all), such as a feeling “high” or blurry. An effect that enables establishing an optimal daily life routine (going to work, meeting with friends, spending time with family…)
And it's much safer, too!
Each inhalation delivers a daily dose of THC that is 79X lower1 compared to THC-rich medical cannabis products2. A dose that prevents the need to switch to a higher dosage than required to reduce the pain’s intensity.
Read more about the unique technology of the SyqeAir Inhaler>>
- Aviram J, et al. (2022) PAIN Reports. 7(3). e1011.
- Aviram, J. (2021). Pharmacological Research, 169, 105651.
